Livros 2022
DOI: 10.38116/978-65-5635-046-2/capitulo10
|View full text |Cite
|
Sign up to set email alerts
|

Desdobramentos Da Nova Lei De Licitações Nas Parcerias Para O Desenvolvimento Produtivo De Saúde

Abstract: As parcerias para o desenvolvimento produtivo (PDPs) são uma modalidade de compra pública para a inovação em que o próprio Estado é o usuário final do resultado da compra. Trata-se, assim, de um instrumento de promoção da inovação pelo lado da demanda (Rauen, 2017), e seu marco regulatório vigente está consubstanciado na Portaria do Ministério da Saúde n o 2.531, de 2014. No âmbito do processo inovativo, as PDPs se posicionam na fase de difusão, isto é, buscam principalmente promover a disseminação e a absorçã… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 1 publication
0
3
0
Order By: Relevance
“…In these contracts, private companies were expected to develop and transfer technology to public laboratories, while a pharma-chemical firm based in Brazil 29 was responsible for internalizing the production of the active pharmaceutical ingredient. By meeting these requirements, companies could sell this medicine faster, being exempt from compliance with the usually long procurement process (Pimentel et al, 2022). Like the Profarma programme, this led to the development of new products for national pharmaceutical companies.…”
Section: Renato H De Gaspi and Pedro Perfeito Da Silvamentioning
confidence: 99%
See 1 more Smart Citation
“…In these contracts, private companies were expected to develop and transfer technology to public laboratories, while a pharma-chemical firm based in Brazil 29 was responsible for internalizing the production of the active pharmaceutical ingredient. By meeting these requirements, companies could sell this medicine faster, being exempt from compliance with the usually long procurement process (Pimentel et al, 2022). Like the Profarma programme, this led to the development of new products for national pharmaceutical companies.…”
Section: Renato H De Gaspi and Pedro Perfeito Da Silvamentioning
confidence: 99%
“…31 As such, in terms of current account repercussions, although the national pharmaceutical sector grew substantially, its production was mostly focused on the domestic market and continued to rely heavily on imported chemical inputs. 32 In addition to this negative result, and even though some incremental innovation came to fruition, this process was overly concentrated within large companies and was incomplete (Pimentel et al, 2022).…”
Section: Renato H De Gaspi and Pedro Perfeito Da Silvamentioning
confidence: 99%
“…Since 2008, public laboratories have increased their investments in biopharmaceuticals due to their new role in expanding the local production of high-cost medicines through PDPs to reduce national technological dependence (Hasenclever et al 2018). The Oswaldo Cruz Foundation (Fiocruz) and the Butantan Institute are the first and fourth public laboratories with partnerships signed between 2009 and 2017 (Pimentel 2018). Not coincidentally, both have been key actors in the production of vaccines for the National Immunisation Plan and, in 2021, in the local production of COVID-19 vaccines .…”
Section: Production and Technological Capacity: Companies And Public ...mentioning
confidence: 99%